Completed PHASE2 INTERVENTIONAL 3-arm NCT01270152

Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter

Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter.

Sponsor: University of Sao Paulo

Conditions Occluded Totally Implanted Central Venous Catheter

Interventions Ascorbic Acid

Updated 4 times since 2017 Last updated: Jan 4, 2011 Started: Oct 31, 2008 Primary completion: Dec 31, 2009 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Occluded Totally Implanted Central Venous Catheter and is currently completed. University of Sao Paulo leads this study, which shows 4 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Sao Paulo

Data source: University of Sao Paulo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ribeirão Preto, Brazil